Clinical Trial Update: Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating prognostic factors in ovarian cancer patients treated with carboplatin, paclitaxel, and bevacizumab.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: National Cancer Institute, Naples | Conditions: Ovarian Cancer | Phase 4 | Status: UNKNOWN